TB Archives – Page 10 of 55 – Treatment Action Group

ACTIVISM DELIVERS UNPRECEDENTED VICTORIES IN TB TESTING AND TREATMENT ACCESS

November 7, 2023
Jason Kirk

Three recent announcements of tuberculosis (TB) medicine and diagnostics price reductions access will enable millions more people to receive TB preventive therapy, and to be tested and treated for TB. Announced alongside the United Nations General Assembly High-Level Meeting on Tuberculosis (TB) in September, these victories across the cascade of TB care were the result of years of targeted, spirited, and informed mobilization from the TB community.

Treatment Action Group Calls for Immediate Ceasefire in Gaza to Protect Health and Lives

November 6, 2023
Jason Kirk

Treatment Action Group (TAG) urgently calls for an immediate ceasefire in Gaza. We grieve Israeli and Palestinian lives lost before, on, and since October 7, and unequivocally condemn the Hamas attacks that killed more than 1,400 Israelis, including some 30 children.

TAG Condemns GSK Actions Surrounding Potential TB Vaccine Revealed by Bombshell ProPublica Report

October 6, 2023
Jason Kirk

TAG is appalled by the revelations set forth in Anna Marie Barry-Jester’s deeply reported investigation for ProPublica, “How a Big Pharma Company Stalled a Potentially Lifesaving Vaccine in Pursuit of Bigger Profits,” published online October 4.

October 2023 TAGline cover: Lost in Translation. Features graphic of "TAG Translate" and shows 4 sets of terms: Shorter Treatments = Error: Insufficient Funding; Community Engagement = Error: political hostility; effective prevention = error inadequate awareness; broad screening = error: outdated guidelines

TAGline October 2023

October 4, 2023
Jason Kirk

We’re thrilled to share the 2023 edition of TAGline, which explores some of the barriers that obstruct research from being effectively implemented to improve people’s health.

TAG Reacts to J&J Commitment to Not Enforce Patents on Bedaquiline

October 2, 2023
Jason Kirk

TAG is thrilled by this weekend’s announcement that following years of activist pressure, Johnson & Johnson (J&J) has finally publicly committed to not enforcing its spurious secondary patents on bedaquiline in the treatment of drug-resistant tuberculosis (DR-TB) in 134 low- and middle-income countries.

TAG Remarks Submitted to United Nation High-Level Meetings (UN HLMs), September 2023

September 27, 2023
Jason Kirk

TAG prepared these remarks to deliver at United Nations High-Level Meetings (UN HLMs) on tuberculosis (TB), universal health coverage (UHC), and pandemic prevention, preparedness, and response (PPR). While we welcome public reaffirmation of commitments to end TB, we urge member…

TAG Response to TB Preventive Therapy Price Cut Announcement from USAID and PEPFAR

September 22, 2023
Jason Kirk

TAG welcomes the joint announcement from USAID and PEPFAR at the CDC’s “Prevent TB to End TB” event on the sidelines of the United Nations High-Level Meeting on TB that they have secured a 30% price reduction on the tuberculosis preventive treatment (TPT) regimen called 3HP, taking the price from $14.25 to $9.99 for a three-month patient course.

New TAG Analysis: Nearly All Countries “Far Off Track” of Meeting TB Research Targets Despite Publicly Reaffirming Commitments at UN

September 20, 2023
Jason Kirk

As international dignitaries and political leaders gather in New York City this week for the United Nations High-Level Meeting (HLM) on TB, a sobering new analysis from Treatment Action Group (TAG) shows that governments failed to meet previous commitments to fund TB research.

At This Week’s UN General Assembly High-Level Meeting on Tuberculosis, the 1/4/6×24 Campaign Calls on Political Leaders to Take Urgent Action for Equitable Access to Shorter, Safer TB Regimens

September 19, 2023
Jason Kirk

Ahead of the United Nations General Assembly High-Level Meeting on the Fight Against Tuberculosis, the 1/4/6x24 Campaign is sounding the alarm that the political declaration commits neither the funding nor the actions needed to expand access to the best-available TB regimens and diagnostics.

TAG Reaction to the Price of GeneXpert Tests

September 19, 2023
Jason Kirk

Following intense pressure from TB-affected communities and civil society, Danaher’s price reduction of Xpert tests for TB and resistance to rifampicin (MTB/RIF Ultra) from $9.98 to $7.97 is a significant step forward that will help increase access to a lifesaving TB test and support countries to make progress toward closing major gaps in TB diagnosis.